# Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)

> **NCT00427921** · PHASE3 · COMPLETED · sponsor: **Abbott** · enrollment: 304 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **BIOLOGICAL:** adalimumab

## Key facts

- **NCT ID:** NCT00427921
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 304 (ACTUAL)
- **Last updated:** 2009-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00427921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00427921, "Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00427921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*